Intae Lee1. 1. University of Pennsylvania, Department of Radiology, B6 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6069, USA. intaelee@gmail.com
Abstract
BACKGROUND: Ranpirnase, a cytotoxic amphibian ribonuclease, is effective against cancer cells, inducing apoptosis independently of p53 protein. Onconase (the smallest member of the RNase A superfamily) has moved into clinical testing in the US and Europe. OBJECTIVE: The main focuses of this review are to examine the manipulation of tumour physiological parameters by ranpirnase and discuss its molecular, pharmacological and physiological roles in preclinical and clinical trials in terms of benefits and toxicity. METHODS: Relevant literature, including the author's unpublished presentations at recent conferences, was examined. RESULTS/ CONCLUSION: In animal studies, improvements in tumour physiology (i.e., increased blood flow, inhibited oxygen consumption, increased oxygenation and decreased tumour hypertension) and selectively enhanced radiation responses (i.e., increased radiation sensitivity and inhibited repair of sublethal and potentially lethal damage) were observed after ranpirnase treatment in preclinical tumour models. Ranpirnase is a promising candidate as an enhancer for radiation- and chemotherapy. Ongoing clinical trials promise to further improve the treatment of mesothelioma and lung cancer.
BACKGROUND: Ranpirnase, a cytotoxic amphibian ribonuclease, is effective against cancer cells, inducing apoptosis independently of p53 protein. Onconase (the smallest member of the RNase A superfamily) has moved into clinical testing in the US and Europe. OBJECTIVE: The main focuses of this review are to examine the manipulation of tumour physiological parameters by ranpirnase and discuss its molecular, pharmacological and physiological roles in preclinical and clinical trials in terms of benefits and toxicity. METHODS: Relevant literature, including the author's unpublished presentations at recent conferences, was examined. RESULTS/ CONCLUSION: In animal studies, improvements in tumour physiology (i.e., increased blood flow, inhibited oxygen consumption, increased oxygenation and decreased tumour hypertension) and selectively enhanced radiation responses (i.e., increased radiation sensitivity and inhibited repair of sublethal and potentially lethal damage) were observed after ranpirnase treatment in preclinical tumour models. Ranpirnase is a promising candidate as an enhancer for radiation- and chemotherapy. Ongoing clinical trials promise to further improve the treatment of mesothelioma and lung cancer.
Authors: Masaki Nasu; Michele Carbone; Giovanni Gaudino; Bevan H Ly; Pietro Bertino; David Shimizu; Paul Morris; Harvey I Pass; Haining Yang Journal: Genes Cancer Date: 2011-05
Authors: Thomas Schirrmann; André Frenzel; Lars Linden; Beatrix Stelte-Ludwig; Jörg Willuda; Axel Harrenga; Stefan Dübel; Beate Müller-Tiemann; Mark Trautwein Journal: MAbs Date: 2014-01-15 Impact factor: 5.857
Authors: C M Goparaju; J D Blasberg; S Volinia; J Palatini; S Ivanov; J S Donington; C Croce; M Carbone; H Yang; H I Pass Journal: Oncogene Date: 2011-02-14 Impact factor: 9.867
Authors: Sandra Jordaan; Olusiji A Akinrinmade; Thomas Nachreiner; Christian Cremer; Krupa Naran; Shivan Chetty; Stefan Barth Journal: Biomedicines Date: 2018-03-05